Should Illumina worry about the Thermo Fisher - Life Technologies deal?

It was certainly a big "deal" when Thermo Fisher announced on April 15 that it had agreed to buy Life Technologies for $13.6 billion, or $76 per share. The proposed merger is the biggest so far in 2013. Although Thermo Fisher offered a 12% premium, Life Technologies' shareholders are looking for ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Molzym

Company Profile | June 17, 2021

Molzym was founded by Michael Lorenz in 2003 and was acquired by Gradian Diagnostics in December 2019 The company's core technology is a culture‑free enrichment method for bacterial and fungal DNA, which it sells as a kit or different components of the kit as needed by the end user It also ... Not part of subscription

OriCiro Genomics raises ¥1 billion (~$9 million) Series B for DNA technology

News Commentary | July 29, 2021

The Japanese startup develops tools for the synthesis and amplification of DNA. The company claims improvements over the traditional PCR and E. coli cloning techniques through the use of an isothermal and cell‑free process. OriCiro plans to use the funds in order to expand its manufacturing ... Not part of subscription

Human Genomics

Technology | August 25, 2021

The sequencing, analysis, and interpretation of the human genome, which leads to therapeutic, diagnostic, and wellness applications. Not part of subscription